Neurological diagnostic and monitoring equipment are used in the diagnosis of various neurological disorders.
Medical Device Network lists the top five companies developing neurology equipment, based on the number of devices in the pipeline, using data from GlobalData’s Medical Intelligence Center.
Go deeper with GlobalData
Irras AB
Neurology medical devices in Irras’ development pipeline account for 3% of the world’s neurology product pipeline as tracked by GlobalData, making it the company with the most number of products in the pipeline.
Irras’ neurology development pipeline includes equipment such as cranial access kits, Bolt-based parenchymal ICP monitoring devices, ventricular catheters, control modules, and CNS systems.
A majority of 54% of the pipeline products are in the clinical stage of development, while the remaining are in the approval process.
Central nervous system diseases and haemorrhagic stroke are the top indications in Irras’ development pipeline.
Nexstim Plc
Nexstim’ development pipeline includes equipment such as cortical stimulators, neuromodulation devices, and spinal cord stimulators, a majority of them being cortical stimulators.
More than 90% of the company’s neurology pipeline products are in clinical stage.
The majority of the equipment in the company’s neurology development pipeline are for brain stroke and neuropathic pain.
Soterix Medical Inc
Neuromodulation devices form the majority of Soterix Medical’s neurology product pipeline, while the company is also developing spinal cord stimulators.
The company’s neurology pipeline products are currently in the clinical stage. Most of the products are being developed in the US.
Depression is the indication with the maximum number of pipeline products by Soterix Medical while other major indications for which the company is developing neurology equipment include fibromyalgia and migraine.
Neural Diagnostics Pty Ltd
Neural Diagnostics has a pipeline of neurological diagnostic and monitoring equipment in the clinical stage.
The products are being developed in the US and Australia and are for different indications some of which include Alzheimer’s disease, attention deficit hyperactivity disorder, and bipolar disorder.
Integra LifeSciences Holdings Corp
Hydrocephalus shunts form the majority of neurology pipeline products of Integra LifeSciences. The company is also developing neurosurgical products, along with many other neurology equipment solutions in its current pipeline.
Among the products, 36% are in the clinical stage and 26% are in the approval process. Country-wise, China and US have the maximum number of pipeline products.
The majority of the products is indicated for hydrocephalus.
